Filing Details

Accession Number:
0001209191-19-013671
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-02-26 17:44:16
Reporting Period:
2019-02-22
Accepted Time:
2019-02-26 17:44:16
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1689813 Biohaven Pharmaceutical Holding Co Ltd. BHVN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1704234 Declan Doogan C/O Biohaven Pharmaceuticals
215 Church Street
New Haven CT 06510
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Shares Disposition 2019-02-22 5,575 $44.11 458,338 No 4 S Direct
Common Shares Disposition 2019-02-22 16,050 $44.97 442,288 No 4 S Direct
Common Shares Disposition 2019-02-25 20,334 $45.25 421,954 No 4 S Direct
Common Shares Disposition 2019-02-25 100 $45.74 421,854 No 4 S Direct
Common Shares Disposition 2019-02-26 20,796 $44.31 401,058 No 4 S Direct
Common Shares Disposition 2019-02-26 100 $44.81 400,958 No 4 S Direct
Common Shares Disposition 2019-02-25 13,943 $45.49 1,099,981 No 4 S Indirect By the Declan Doogan 2014 Trust
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Indirect By the Declan Doogan 2014 Trust
Footnotes
  1. These sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.54 - $44.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.55 - $45.31, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.70 - $45.645, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.79 - $44.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
  6. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.41 - $46.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.